Discover and validate new capabilities using the iQue Screener for research or for commercialization.
Once accepted into TAP, IntelliCyt will support proof-of-concept studies or validation screens in your own facilities in collaboration with our team. We will help you raise grant money, develop a new assay or assay technology, or even partner in commercializing an application together. If you are a technology provider with reagents or assays, we are also interested in collaborating in validation studies to bring more turnkey applications to our users.
Submit a proposal using TAP’s brief application process.
GPCRs are an important class of proteins for therapeutic development. SpectraGenetics has a full line of tagged GPCRs and validated cell lines for GPCR Internalization, trafficking and screening. Homogeneous assays utilizing Fluorogen Activating Peptide (FAP) technology have proven to be very valuable for measuring GPCR internalization and trafficking. SpectraGenetics’ access to the IntelliCyt iQue® Screener instrument and ForeCyt® software will further the development of a new type of internalization and trafficking assay for G-Protein Coupled Receptors (GPCR’s), an important class of proteins for therapeutic development. The combination of this assay with the IntelliCyt iQue Screener’s ability to measure 50,000 wells per day in 96-, 384- or 1536-well microplates, will enable assessment of very large (1,000,000+) primary compound screens.”
Dr. Sykes was awarded the first TAP to accelerate his pursuit of therapeutic options for AML (Acute Myeloid Leukemia) combining the clinical and screening expertise of scientists from the Massachusetts General Hospital and the Broad Institute with IntelliCyt’s iQue Screener. His TAP award follows earlier work using High Throughput Flow for screening compound libraries at the University of New Mexico in collaboration with Dr. Larry Sklar.
Acute Myeloid Leukemia (AML) is a devastating disease with a 5-year survival rate of only 25%. One exception has been the discovery of drugs which trigger cellular differentiation in the 10% of patients with acute promyelocytic leukemia. Differentiation therapies are well tolerated and extremely effective, leading to 5-year survival rates approaching 80% in this small subset of patients with acute promyelocytic leukemia.
Unfortunately differentiation therapy is currently not available for the remaining 90% of patients with AML. I am interested in understanding what establishes differentiation in acute myeloid leukemia. Furthermore, I am interested in identifying new compounds which can modulate differentiation as candidates for treating human leukemia.
More about Dr. Sykes and his research